Haleon plc (HLN) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Weybridge, United Kingdom. Le PDG actuel est Brian James McNamara.
HLN a date d'introduction en bourse 2022-07-25, 24,561 employés à temps plein, cotée sur le NYSE, une capitalisation boursière de $43.23B.
Haleon plc is a consumer healthcare company headquartered in Brentford, United Kingdom, engaged in the research, development, manufacture, and distribution of over-the-counter health and wellness products across North America, Europe, the Middle East, Africa, Latin America, and Asia Pacific. The company's extensive portfolio spans therapeutic oral health, pain relief, respiratory health, digestive health, vitamins, minerals, and supplements, featuring globally recognized brands including Panadol, Voltaren, Advil, Sensodyne, Theraflu, Otrivin, Polident, parodontax, and Centrum. Since its incorporation in 2021 and rebranding to Haleon plc in February 2022, the company has positioned itself as a leading player in the consumer healthcare sector.
